BioCentury | Feb 9, 2021
Product Development
KalVista gains on Phase II data for oral HAE treatment
...By Danielle Golovin, Staff Writer KalVista gained $17.89 (114%) to $33.50 on Tuesday after reporting its...
...PGI-C) scale and achieved symptom relief more quickly (p<0.0001) using a composite Visual Analogue Scale (VAS).KalVista...
...Pharmaceuticals Inc. (NASDAQ:BCRX), marking the first approval for an orally administered non-steroidal option to prevent HAE. KalVista...
...PGI-C) scale and achieved symptom relief more quickly (p<0.0001) using a composite Visual Analogue Scale (VAS).KalVista...
...Pharmaceuticals Inc. (NASDAQ:BCRX), marking the first approval for an orally administered non-steroidal option to prevent HAE. KalVista...